NT5C and acute lymphoblastic leukemia: Mutations in the nucleotidase NT5C that are recurrent in T-ALL (Tzoneva et al., 2013, 2018) may confer resistance to mercaptopurine, a key element in ALL therapy, representing a typical example of gain-of-function mutations that are difficult to target, which is in addition also associated with occurrence of relapse.